Fresenius Partners with WuXi Biologics in Exclusive Agreement to Expand Biosimilars Pipeline to 66 Molecules
Fresenius SE & Co. KGaA has announced an exclusive development agreement with WuXi Biologics, a global contract research, development and manufacturing organization, to significantly expand its biosimilars pipeline and strengthen its position in the global biopharmaceutical market.
The agreement is expected to provide Fresenius with access to as many as 37 additional biosimilar development candidates over the next decade. Through this collaboration, the company aims to increase its existing portfolio from 29 marketed and pipeline molecules to as many as 66 molecules, creating new opportunities to expand its presence across multiple therapeutic areas.
The partnership represents an important step in Fresenius’ long-term biopharmaceutical growth strategy. By combining WuXi Biologics’ development and manufacturing capabilities with Fresenius’ global commercial infrastructure, the companies aim to accelerate the development of biosimilar medicines and expand access to biologic treatments.
According to Fresenius, the expanded portfolio could address more than €370 billion in originator list-price-based sales. The agreement is also expected to support the company’s biopharma business beyond its existing 2030 growth ambitions while maintaining a disciplined approach to investment and capital allocation.
Exclusive Agreement Provides Access to 37 Biosimilar Candidates
Under the terms of the agreement, Fresenius will receive exclusive access to up to 37 identified biosimilar candidates for potential development over the next ten years.
The collaboration is described by Fresenius as the largest development agreement announced in the biosimilars industry to date. It is intended to provide a scalable approach to expanding the company’s product pipeline without requiring Fresenius to independently develop every candidate through its internal research and development operations.
The development candidates will be evaluated and selected according to Fresenius’ established investment and product-selection criteria. These criteria include market attractiveness, development risks and expected financial returns.
This approach will allow the company to prioritize opportunities based on their potential commercial value and development feasibility. Rather than advancing every available candidate, Fresenius will focus its resources on programs that align with its strategic objectives and long-term business plans.
An important component of the agreement is the ownership structure associated with successfully commercialized products. Fresenius will retain exclusive global commercialization rights, including marketing authorizations, as well as the full economics of each product commercialized under the agreement.
This arrangement is expected to give Fresenius control over the commercial strategy and financial benefits associated with the products developed through the collaboration.
For the company, the agreement provides access to a broader range of development opportunities while preserving strategic flexibility. It also allows Fresenius to determine which candidates should receive investment based on changing market conditions, competitive dynamics and anticipated commercial demand.
Fresenius Strengthens Its Biopharma Growth Strategy
The partnership with WuXi Biologics forms part of Fresenius’ broader strategy to expand its biopharmaceutical business and strengthen its position in the biosimilars market.
Michael Sen, Chief Executive Officer of Fresenius, highlighted the importance of the agreement in supporting the company’s long-term growth ambitions.
He said Fresenius is increasing its commitment to the Biopharma business through access to development capabilities in a market where speed and scale are increasingly important.
Sen explained that the collaboration provides a disciplined and scalable opportunity to potentially triple the company’s portfolio while retaining economic ownership, strategic control and flexibility in capital allocation.
He also emphasized that the agreement, combined with Fresenius’ full ownership of mAbxience, is expected to support biopharmaceutical growth well beyond 2030.
The company’s strategy reflects the growing importance of biosimilars in the global healthcare market. As more biologic medicines approach patent expiration, biosimilar developers have opportunities to introduce alternative treatment options and expand competition across established therapeutic categories.
However, developing biosimilars requires substantial technical expertise, investment and manufacturing capabilities. Companies must demonstrate that their products are highly similar to approved reference biologics and meet applicable quality, safety and efficacy requirements.
Through its agreement with WuXi Biologics, Fresenius aims to access established development capabilities and expand the number of potential products available for future commercialization.
The partnership also provides an opportunity to build a more diversified pipeline, reducing dependence on individual products and creating additional growth opportunities across different medical specialties.
Pipeline Expansion Across 13 Therapeutic Areas
The expanded biosimilars portfolio is expected to cover 13 therapeutic areas, allowing Fresenius to strengthen its existing market positions while entering additional areas of medicine.
The company’s established positions in oncology, immunology and gastroenterology are expected to receive further support through the new development opportunities.
At the same time, the expanded pipeline will create opportunities to enter therapeutic areas such as neurology, nephrology and cardiopulmonary medicine.
These areas represent important opportunities for biosimilar development because biologic therapies play an increasingly significant role in treating complex and chronic diseases.
In oncology, biologic medicines are widely used in the treatment of several types of cancer. Biosimilar development in this area may help introduce additional treatment options and increase competition within the market.
Immunology is another important therapeutic category, with biologic medicines used to manage inflammatory and autoimmune conditions. Gastroenterology also represents a significant market for biologic treatments used in certain chronic digestive and inflammatory diseases.
The planned expansion into neurology could provide Fresenius with access to additional opportunities involving complex neurological disorders. Similarly, nephrology represents an important area for treatments addressing kidney-related conditions, while cardiopulmonary medicine includes therapies targeting heart and lung diseases.
By diversifying across these therapeutic categories, Fresenius aims to establish a broader and more sustainable biosimilars portfolio.
The expanded pipeline will also include several biologic technology platforms, including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates and fusion proteins.
These technologies represent different approaches to developing targeted biologic medicines and provide opportunities to address a variety of diseases.
Initial Development Focuses on Two Promising Candidates
The initial development activities under the agreement are expected to focus on two biosimilar candidates: polatuzumab vedotin and teprotumumab.
Polatuzumab vedotin is an antibody-drug conjugate used in the treatment of diffuse large B-cell lymphoma, a type of non-Hodgkin lymphoma that affects B lymphocytes.
Antibody-drug conjugates combine the targeting capabilities of antibodies with therapeutic agents designed to act against cancer cells. This approach is intended to deliver treatment more selectively to targeted cells.
Diffuse large B-cell lymphoma is an aggressive form of blood cancer, and treatment options may involve different combinations of chemotherapy, immunotherapy and targeted medicines depending on the patient’s condition.
The development of a biosimilar candidate involving polatuzumab vedotin would place Fresenius in an important oncology segment where targeted biologic therapies play a role in treatment.
The second initial candidate, teprotumumab, is a monoclonal antibody used for the treatment of thyroid eye disease.
Thyroid eye disease is an autoimmune condition that can cause inflammation and swelling of tissues around the eyes. In some patients, the condition may lead to eye discomfort, bulging eyes, double vision and other complications that can affect daily activities.
Monoclonal antibody therapies are designed to target specific biological pathways involved in disease development. Teprotumumab provides a targeted treatment approach for eligible patients with thyroid eye disease.
The selection of these two candidates demonstrates the range of technologies and therapeutic areas that Fresenius intends to explore through the collaboration.
Both development programs will need to progress through the relevant technical, clinical and regulatory requirements before any potential commercial launch.
WuXi Biologics Brings Global Development and Manufacturing Expertise
WuXi Biologics will play a central role in supporting the expanded development pipeline through its established capabilities in biologics research, development and manufacturing.
The company operates as a global contract organization serving the biopharmaceutical industry. Its capabilities include large-scale biologics development and manufacturing, with experience across monoclonal antibodies, bispecific antibodies and antibody-drug conjugates.
These capabilities are particularly relevant to biosimilar development, which requires specialized scientific expertise, advanced manufacturing processes and the ability to produce biologic medicines consistently at commercial scale.
Unlike many traditional small-molecule medicines, biologics are produced using living systems and involve complex manufacturing processes. Maintaining product quality and consistency is therefore an important consideration throughout development and commercialization.
WuXi Biologics’ experience in these areas is expected to support Fresenius in evaluating and advancing potential biosimilar candidates.
The company’s international network also represents an important element of the collaboration. Its operations span Europe, the United States, China and Singapore, providing access to development and manufacturing capabilities across multiple regions.
Development activities under the agreement are expected to be conducted through WuXi Biologics’ global network.
This international footprint could help support the development of products intended for global markets while providing access to different technical resources and manufacturing capabilities.
For Fresenius, working with an established development partner offers an opportunity to expand its pipeline while leveraging external expertise and infrastructure.
Combining External Collaboration With Internal Research and Development
The agreement is part of Fresenius’ balanced approach to expanding its biosimilars portfolio through internal research and development, strategic collaborations and selective in-licensing arrangements.
This strategy allows the company to access development opportunities from different sources rather than depending entirely on internally generated candidates.
Internal research and development remains an important part of the company’s biopharmaceutical activities. However, collaborations with external organizations can provide access to additional technologies, scientific capabilities and potential product candidates.
The partnership with WuXi Biologics is expected to strengthen this approach by creating a larger pool of potential biosimilar programs.
Fresenius will evaluate candidates based on their market opportunities, technical feasibility, development risks and expected returns. This selection process is intended to ensure that investment decisions remain aligned with the company’s financial and strategic priorities.
The company will also retain flexibility to decide which development programs should move forward, allowing it to manage its investment commitments over time.
This model is particularly relevant in the biosimilars market, where development timelines, regulatory requirements and commercial competition can vary significantly between products.
mAbxience Acquisition Adds Further Strategic Value
Fresenius’ collaboration with WuXi Biologics also builds on its recent acquisition of mAbxience, a Spain-headquartered biopharmaceutical company.
The full ownership of mAbxience provides Fresenius with an additional platform to strengthen its capabilities across the biopharmaceutical value chain.
By combining the mAbxience platform with access to WuXi Biologics’ development and manufacturing network, Fresenius aims to expand the number of potential biosimilar candidates it can evaluate and advance.
The strategy is designed to create opportunities across several stages of the product lifecycle, including development, manufacturing and commercialization.
This broader operating model could help Fresenius capture greater value from successfully developed products while building a more diversified business.
The collaboration also provides access to a wider global biotechnology landscape, allowing Fresenius to identify opportunities that may complement its existing portfolio and therapeutic expertise.
Rather than relying on a single development approach, the company is combining its internal platform, external partnerships and selective licensing activities to support long-term growth.
Global Biosimilars Market Creates New Opportunities
The agreement comes as the global biosimilars industry continues to develop, with healthcare systems increasingly focused on treatment affordability, access and competition.
Biosimilars are highly similar versions of already approved biologic medicines. They are developed after the loss of exclusivity of reference biologics and must meet regulatory requirements demonstrating similarity in quality, safety and efficacy.
These medicines can introduce additional competition into markets previously dominated by a limited number of biologic products.
For healthcare providers and health systems, increased biosimilar availability may create additional treatment choices and opportunities to manage pharmaceutical spending.
However, successful biosimilar development requires companies to navigate complex scientific, manufacturing, clinical and regulatory processes.
Fresenius’ agreement with WuXi Biologics is intended to strengthen its ability to participate in this market by providing access to a larger development pipeline and global technical capabilities.
The potential portfolio expansion from 29 to as many as 66 molecules represents a substantial increase in the company’s development opportunities. The estimated addressable market of more than €370 billion in originator list-price-based sales further illustrates the commercial scale of the opportunity identified by Fresenius.
Long-Term Outlook for Fresenius Biopharma
Through the exclusive agreement, Fresenius is positioning its biopharmaceutical business for further expansion over the coming decade.
The collaboration provides access to as many as 37 additional biosimilar candidates, expands the potential portfolio across 13 therapeutic areas and introduces opportunities involving several advanced biologic technologies.
The company’s decision to retain exclusive global commercialization rights and the full economics of each commercialized product also gives it a central role in the future commercial development of the selected candidates.
Combined with its internal research capabilities, targeted collaborations and full ownership of mAbxience, the agreement creates a broader foundation for Fresenius’ biopharma strategy.
The partnership is expected to support the company’s ambitions beyond 2030 while maintaining a disciplined approach to development investments and capital allocation.
As the selected candidates progress through development, manufacturing and regulatory evaluation, Fresenius will have opportunities to build a more diversified biosimilars portfolio and strengthen its presence across global therapeutic markets.
Ultimately, the agreement with WuXi Biologics represents a major expansion of Fresenius’ biopharmaceutical development strategy, bringing together global expertise, scalable manufacturing capabilities and commercial ownership to support the company’s long-term growth in the biosimilars industry.
Source link: https://www.fresenius.com/
